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Introduction
E sophageal cancer (EC) is the eighth common cancer world-wide and was reported as the sixth most common cause of death from cancer.1 Considerable variations were reported 
for the incidence of EC between different parts of the world. A 
geographic area extending from northern Iran to north-central Chi-
na (Asian belt of EC) was considered as a high-risk area for EC.2–4 
Squamous cell carcinoma (SCC) and adenocarcinoma are the most 
common types of EC.2–5 Reports in the 1960,s suggested that the 
morphologic diagnosis in about 90% of EC cases was esophageal 
SCC (ESCC).3 ESCC is still more frequent than esophageal adeno-
carcinoma (EAD) worldwide, especially in the developing coun-
tries.6,7 But, many recent reports showed an increasing trend in 
EAD and a decreasing trend in ESCC in many Western coun-
tries.8–13 Age, male gender, tobacco smoking, gastroesophageal re-
ÀX[GLVHDVH*(5'REHVLW\DQGK\SHUWHQVLRQ14–16 were proposed 
as possible risk factors of EAD. 
Some reports suggested that the prevalence of some of these 
risk factors including hypertension and obesity is increasing in 
low- and middle-income countries.17–20 This is partly due to rapid 
modernization and lifestyle changes including dietary changes, 
improved living conditions, and a decrease in physical activity.21 
So, it may be expected that the rate of EAD is also increasing in 
the developing world.    
Golestan Province, located in northeast of Iran, has been known 
as a high-risk area for EC.2,22 The results of a study in 2004 showed 
that ESCC included 91% of EC cases in GolestanProvince.23 Re-
cently, a high prevalence rate of some risk factors of EAD, includ-
ing obesity, was reported from this region,24 suggesting the possi-
bility of an increase in the incidence rate of EDA in this high- risk 
area. The aim of this study was to describe the time trend of EAD 
in Golestan Province of Iran between 2000 – 2009.
Materials and Methods
Study population
This study was done in Golestan Province, located in northeast 
of Iran. Data on cancer cases during the period of 2000–2009 
were obtained from Golestan Population-based Cancer Registry 
*3&5DQG&DQFHU2I¿FHRI WKH+HDOWK'HSDUWPHQWRI*ROHV-
tan University of Medical Sciences. Esophageal and gastric cancer 
FDVHVZLWKKLVWRORJLFFRQ¿UPDWLRQZHUHUHFUXLWHG'DWDRQ*ROHV-
tan population were obtained from Provincial Census done by the 
Health Department of Golestan University of Medical Sciences. 
Incidence Rates
Age-standardized incidence rates (ASRs) were calculated us-
ing direct standardization method. World standard population (18 
groups) was considered and the rates were expressed per 1,000,000 
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)*KDVHPL.HEULD*5RVKDQGHO66HPQDQLHWDO
SHUVRQ\HDUV$W¿UVWWKHRYHUDOOWUHQGRI(&LQFLGHQFHZDVH[DP-
ined. Then, the incidence trends of EAD were provided for total 
studied population as well as for males and females, separately. 
7RDVVHVVWKHSRVVLELOLW\RIKLVWRORJLFPLVFODVVL¿FDWLRQLIZKDW
was once called SCC of the esophagus is now called adenocar-
cinoma of the esophagus), we examined the trend of ESCC. The 
incidence trend of gastric adenocarcinoma was examined to de-
WHUPLQH LIDQDWRPLFPLVFODVVL¿FDWLRQZDVRFFXUUHGLIZKDWZDV
once called adenocarcinoma of the stomach is now called adeno-
carcinoma of the esophagus). In order to assess the possibility of 
DQDWRPLFPLVFODVVL¿FDWLRQSUHFLVHO\ZHQHHGHGWKHGDWDRQDGHQR-
carcinoma of the gastric cardia. As these data were not available 
in GPCR, we used the data from Atrak Clinic, which is a research, 
diagnostic, and therapeutic center located in Gonbad City, eastern 
part of Golestan Province. It provides medical services to patients 
with upper gastrointestinal (GI) problems in the region. Recent re-
ports suggest that about 70% of upper GI cancer cases in eastern 
parts of Golestan Province refer to Atrak Clinic. Detailed informa-
tion about anatomic sub-site and histologic sub-type of upper GI 
cancers is routinely recorded for all patients referred to this center. 
Data on esophageal and gastric cancer cases diagnosed during the 
period of 2002–2009 were obtained from Atrak Clinic. The popu-
ODWLRQIURPZKLFK$WUDNFDVHVFDPHFRXOGQRWEHFOHDUO\GH¿QHG
So, we could not calculate the ASR of adenocarcinoma of the gas-
tric cardia. Instead, we considered the proportion of cases with ad-
enocarcinoma of the gastric cardia to total cases of adenocarcino-
ma in Atrak Clinic (CAD/TAD) for each year. The trend of CAD/
TAD proportion during the period of 2002–2009 was examined. 
To make a comparison, the proportion of cases with adenocarci-
noma of the esophagus to total cases of adenocarcinoma in Atrak 
Clinic (EAD/TAD) was also calculated. 
Statistical analysis
Analysis was done using a Joinpoint software version 3.5.4.25 To 
examine the incidence trends, the annual percent change (APC) 
was calculated by generalized linear models assuming a Poisson 
distribution. A weighted least-squares regression was performed, 
in which the independent variable was the year and the dependent 
variable was the natural logarithm of the incidence rate or propor-
tion. Heteroscedastic errors were assessed based on the number of 
cases in each year using a Poisson model and used for calculating 
FRQ¿GHQFHLQWHUYDOV&,RI$3&-RLQSRLQWUHJUHVVLRQ
analysis26 ZDV XVHG WR FKRRVH WKH EHVW¿WWLQJ SRLQWV WKH µMRLQ-
SRLQWV¶ZKHUHWKHPDJQLWXGHDQGRUGLUHFWLRQRIUDWHVLJQL¿FDQWO\
changed. The Joinpoint permutation test was performed to identify 
VLJQL¿FDQWGLIIHUHQFHV26 Regarding the number of observations in 
our study (lower than 12), a maximum number of one joinpoint 
was allowed for estimations. APCs were separately determined for 
each segment (from start to jointpoint and from jointpoint to the 
end of observation) as well as across the entire range of data (from 
start to the end of observation). The trend was considered as sig-
QL¿FDQWLIWKH&,RI$3&GLGQRWLQFOXGH]HUR$P-value of 
OHVVWKDQZDVFRQVLGHUHGDVVLJQL¿FDQW
Results
$WRWDOQXPEHURIKLVWRORJLFDOO\FRQ¿UPHG(&FDVHVZHUH
diagnosed in Golestan Province during the period of 2000–2009. 
$ERXWRI WKHVHFDVHVZHUHPDOHV:HIRXQGQRVLJQL¿FDQW
trend in the incidence rate of EC during the study period (Table 1). 
7KHLQFLGHQFHUDWHRI($'VKRZHGDVLJQL¿FDQWLQFUHDVLQJWUHQG
)LJXUH2XUUHVXOWVVXJJHVWHGDVLJQL¿FDQWLQFUHDVLQJWUHQGRI
($'LQPDQEXWQRVLJQL¿FDQWFKDQJHZDVVHHQLQWKHLQFLGHQFH
rate of EAD during the study period in women (Figure 2).
7KHUHZDVQRVLJQL¿FDQWWUHQGLQWKH$65RI(6&&GXULQJWKH
VWXG\SHULRG7DEOH$VLJQL¿FDQWLQFUHDVHZDVREVHUYHGLQWKH
incidence rate of gastric adenocarcinoma during the period of 
2000–2005, followed by a plateau during the period of 2005–2009 
(Table 1). Both of EAD/TAD and CAD/TAD proportions showed 
an increasing trend during the period of 2002–2009. The trend of 
&$'7$'SURSRUWLRQZDVVLJQL¿FDQWEXWQRVLJQL¿FDQWFKDQJH
was found in the proportion of EAD/TAD (Figure 3).
Discussion
We found a marked increase in the ASR of EAD in Golestan 
Province of Iran from 1.9 per 1000000 person-years in 2000 to 
19.94 per 1000000 person-years in 2009. Such an increasing trend 
in the incidence rate of EAD was initially reported from Western 
countries.11,12,14,27,28 Change in the prevalence of some risk factors 
including GERD,29 obesity,30 smoking,31 and Helicobacter pylori 
infection32 were suggested as possible explanations for increas-
ing trend of EAD. A number of recent reports also showed a high 
prevalence of such risk factors in developing countries.17,18,20 So, it 
may be expected that the incidence rate of EAD is increasing in 
the developing world. A high prevalence of the risk factors of EAD 
in Iran19,24,33,34 may explain a high incidence of EAD in our area. 
7KHUHIRUHLWVHHPVWKDWRXU¿QGLQJVUHÀHFWDWUXHULVHLQWKHLQFL-
dence rate of EAD in Golestan Province of Iran during the last de-
cade. An increase in the prevalence of EAD in Golestan Province, 
a high-risk area for ESCC,7 seems to be an important health issue. 
Therefore, designing and implementation of control programs, in-
cluding control of preventable risk factors of EAD, should be con-
sidered as a priority of health policy making in this area.
Figure 2 shows that the increasing trend of EAD was observed 
only in males, while the rate of this cancer in females remained 
constant (with a slight increase) during the study period. The re-
sults of previous studies suggested a considerable gender differ-
ence in the incidence of EAD with a sex ratio of 8 – 9: 1 in favor of 
males. Protective effect of estrogen in females has been proposed 
as possible explanation for such difference.35 So, the impact of in-
Trend I Trend II
APC 2000–2009(95% CI) Year APC (95% CI) Year APC (95% CI)
Esophageal cancer 4.6 (-6.1–16.5) 2000–2007 6.1 (-2.6–15.5) 2007–2009 -0.3 (-43.1–74.6)
Esophageal squamous cell carcinoma 3.4 (-7.7–15.8) 2000–2007 5.2 (-3.6–14.9) 2007–2009 -2.8 (-46.4–76.3)
Gastric adenocarcinoma 10.4* (2.8–18.5) 2000–2005 19.3* (5.1–35.4) 2005–2009 0.2 (-12.7–15.0)
$3& DQQXDOSHUFHQWFKDQJH7KH$3&LVVLJQL¿FDQWO\GLIIHUHQWIURP]HURP < 0.05).
Table 1. Trend of age-standardized incidence rate of esophageal cancer, esophageal squamous cell carcinoma, and gastric adenocarcinoma (2000–2009).
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crease in the incidence of EAD is obviously more prominent in 
male gender.
Beside the real increase in the incidence of EAD, other possi-
ELOLWLHVLQFOXGLQJRYHUGLDJQRVLVKLVWRORJLFPLVFODVVL¿FDWLRQDQG
DQDWRPLFPLVFODVVL¿FDWLRQPD\EHSURSRVHGDVSRVVLEOHH[SODQD-
tions for the observed increasing trend in our study.
Over-diagnosis may occur when a screening program is imple-
mented in a population36 or when the diagnostic intensity is in-
creased. No screening program has been implemented for EC in 
this region and other parts of Iran. But, it seems that the diagnostic 
intensity has been increased during the last decade. In other words, 
the number of gastroenterologists as well as diagnostic facilities in-
cluding endoscope sets has been considerably increased in Goles-
tan Province. Such change may result in over-diagnosis of EAD 
and explain the observed rise in the incidence of EAD. But, if that 
was correct, the incidence of ESCC would be expected to similarly 
have increased. But, our results suggested no increase and even a 
slight decrease in the incidence of ESCC during the same period 
(Table 1). So, over-diagnosis may not be considered as a serious 
explanation for the increasing trend of EAD in Golestan Province.
Another possible explanation of the observed rise in the inci-
GHQFHRI($'LVKLVWRORJLFPLVFODVVL¿FDWLRQ,WPD\EHSURSRVHG
WKDWVRPHRI($'FDVHVKDGEHHQZURQJO\FODVVL¿HGDV(6&&DQG
DUHQRZFRUUHFWO\LGHQWL¿HGUHVXOWLQJLQVXFKQRQUHDOLQFUHDVHLQ
WKHLQFLGHQFHRI($',IZHDUHJRLQJWRDFFHSWWKDWDVLJQL¿FDQW
decrease would also be expected in the incidence of ESCC. But, 
we found that the ESCC rate remained constant between 2000–
7DEOH6RKLVWRORJLFPLVFODVVL¿FDWLRQPD\QRWH[SODLQ
the increasing trend of EAD in our area.
$QDWRPLFPLVFODVVL¿FDWLRQZDVDOVRFRQVLGHUHGDVDSRVVLEOHH[-
planation for the rising incidence of EAD. That means some of 
EAD cases might be wrongly diagnosed as adenocarcinoma of the 
VWRPDFKDQGDUHQRZFRUUHFWO\FODVVL¿HGDV($'6XFKFKDQJH
LQFODVVL¿FDWLRQPD\EHSURSRVHGWRFDXVHDIDOVHLQFUHDVHLQWKH
incidence of EAD. But, if that explanation was correct, we might 
not expect a major increase in the incidence of adenocarcinoma 
RIWKHVWRPDFKVSHFL¿FDOO\RI&$'GXULQJWKHVWXG\SHULRG:H
found an increasing trend in the proportion of CAD/TAD (Figure 
3). Furthermore, we found that the incidence of gastric adenocar-
cinoma was approximately doubled in this period (10.4 to 19.3 
per 100,000). If we assume that all of the excess cases of EAD in 
2005–2009 compared to 2000–2005 (28.0–19.1= 8.9 per 100,000), 
were in fact CAD cases, then we would expect a triple increase in 
the incidence of adenocarcinoma of the stomach in 2000–2009. 
Such a high increase in the incidence of CAD in a relatively short 
time and no increase in the EAD incidence may be less likely than 
a real increase in the incidence of both cancers. Therefore, ana-
WRPLFPLVFODVVL¿FDWLRQLVXQOLNHO\WRH[SODLQDOORIWKHLQFUHDVHLQ
the incidence of EAD in our study.
The results of similar studies from other parts of the world also 
Figure 1. Trend of age- standardized incidence rate of EAD in Golestan 
Province, Iran (2000 – 2009). (APC= annual percent change; *The APC is 
VLJQL¿FDQWO\GLIIHUHQFHIURP]HURDWDOSKD 
Figure 2. Trend of age- standardized incidence rate of EAD in males and 
females, Golestan Province, Iran (2000 – 2009). (APC= annual percent 
FKDQJH7KH$3&LVVLJQL¿FDQWO\GLIIHUHQFHIURP]HURDWDOSKD 
Figure 3. Trend of the proportion of EAD and gastric cardia adenocar-
cinoma (CAD) to total cases of adenocarcinoma (TAD), in Atrak Clinic, 
Golestan Province, Iran (2000–2009). (APC = Annual percent change; 
7KH$3&LVVLJQL¿FDQWO\GLIIHUHQFHIURP]HURDWDOSKD 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showed that the increasing trend of EAD could not be explained 
E\PLVFODVVL¿FDWLRQRURYHUGLDJQRVLV$VLQRXUVWXG\WKH\DOVR
found a real rise in the incidence of EAD and concluded that an 
increase in the prevalence of risk factors including smoking, obe-
sity, and GERD is the most appropriate explanation for such an 
increasing trend.37,38
,QFRQFOXVLRQZHIRXQGDVLJQL¿FDQWLQFUHDVLQJWUHQGLQWKHLQ-
cidence rate of EAD in a high ESCC-risk area in northeastern Iran 
GXULQJWKHODVWGHFDGH:H¿QGQRHYLGHQFHWRVXSSRUWDOWHUQDWLYH
H[SODQDWLRQ LQFOXGLQJ RYHUGLDJQRVLV RU DQDWRPLFPLVFODVVL¿FD-
tion of adenocarcinoma of the gastric cardia or histologic mis-
FODVVL¿FDWLRQRI(6&&6RWKHREVHUYHGULVHLQWKHLQFLGHQFHRI
EAD seems to be real. Therefore, designing and implementation 
of control programs, including control of preventable risk factors 
of EAD, should be considered in this high-risk area.
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